Rohan Garje, Aditya Ravindra, Bilal Rahim, Mathew Kroll, Jeffrey S Johnson, Julie Torres, Jaime Bonner, Vignesh T Packiam, Sarah Mott, Michael O'Donnell, Yousef Zakharia
{"title":"Avelumab和紫杉醇化疗治疗铂难治或不符合条件的转移性尿路上皮癌（AVETAX试验）。","authors":"Rohan Garje, Aditya Ravindra, Bilal Rahim, Mathew Kroll, Jeffrey S Johnson, Julie Torres, Jaime Bonner, Vignesh T Packiam, Sarah Mott, Michael O'Donnell, Yousef Zakharia","doi":"10.1016/j.urolonc.2025.04.005","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>This study investigates the role of taxanes and immunotherapy for inoperable advanced or metastatic urothelial carcinoma in patients unable to tolerate or refractory to platinum-based regimens. We aimed to determine the safety and estimate the efficacy of a combination of avelumab and docetaxel in treating advanced or metastatic urothelial carcinoma.</p><p><strong>Methods: </strong>This phase 1b, single-arm, open-label clinical trial involved adults with advanced or metastatic urothelial carcinoma, progressing during or after platinum-containing chemotherapy, within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy, or ineligible for platinum regimens. Primary objectives were determining the maximum tolerated dose (MTD) of docetaxel with avelumab and estimating efficacy via the objective response rate (ORR). In Phase I, docetaxel (45, 60, 75 mg/m²) was combined with 10 mg/kg avelumab every 3 weeks for 6 cycles, followed by avelumab biweekly as maintenance. The expansion cohort received treatment at the MTD of 75 mg/m² docetaxel with 10 mg/kg of avelumab.</p><p><strong>Results: </strong>Twenty-one patients with advanced or metastatic urothelial carcinoma were studied: 8 cisplatin-refractory and 13 cisplatin-ineligible. The 75 mg/m² dose of docetaxel with 10 mg/kg avelumab was safe, with 1 dose-limiting toxicity (neutropenic fever). The ORR was 52.4% (95% CI: 29.8%-74.3%). Median progression-free survival and overall survival were 14.6 months (95% CI: 2.8-15.8) and 16.6 months (95% CI: 13.2-not reached), respectively.</p><p><strong>Conclusion: </strong>The combination of avelumab and docetaxel shows favorable safety and efficacy in treating advanced or metastatic bladder cancer.</p><p><strong>Trial registration: </strong>Funded by Pfizer Pharmaceuticals; AVETAX; https://classic.</p><p><strong>Clinicaltrials: </strong>gov/ct2/show/NCT03575013, NCT03575013.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Avelumab and taxol chemotherapy in platinum-refractory or ineligible metastatic urothelial carcinoma (AVETAX trial).\",\"authors\":\"Rohan Garje, Aditya Ravindra, Bilal Rahim, Mathew Kroll, Jeffrey S Johnson, Julie Torres, Jaime Bonner, Vignesh T Packiam, Sarah Mott, Michael O'Donnell, Yousef Zakharia\",\"doi\":\"10.1016/j.urolonc.2025.04.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objective: </strong>This study investigates the role of taxanes and immunotherapy for inoperable advanced or metastatic urothelial carcinoma in patients unable to tolerate or refractory to platinum-based regimens. We aimed to determine the safety and estimate the efficacy of a combination of avelumab and docetaxel in treating advanced or metastatic urothelial carcinoma.</p><p><strong>Methods: </strong>This phase 1b, single-arm, open-label clinical trial involved adults with advanced or metastatic urothelial carcinoma, progressing during or after platinum-containing chemotherapy, within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy, or ineligible for platinum regimens. Primary objectives were determining the maximum tolerated dose (MTD) of docetaxel with avelumab and estimating efficacy via the objective response rate (ORR). In Phase I, docetaxel (45, 60, 75 mg/m²) was combined with 10 mg/kg avelumab every 3 weeks for 6 cycles, followed by avelumab biweekly as maintenance. The expansion cohort received treatment at the MTD of 75 mg/m² docetaxel with 10 mg/kg of avelumab.</p><p><strong>Results: </strong>Twenty-one patients with advanced or metastatic urothelial carcinoma were studied: 8 cisplatin-refractory and 13 cisplatin-ineligible. The 75 mg/m² dose of docetaxel with 10 mg/kg avelumab was safe, with 1 dose-limiting toxicity (neutropenic fever). The ORR was 52.4% (95% CI: 29.8%-74.3%). Median progression-free survival and overall survival were 14.6 months (95% CI: 2.8-15.8) and 16.6 months (95% CI: 13.2-not reached), respectively.</p><p><strong>Conclusion: </strong>The combination of avelumab and docetaxel shows favorable safety and efficacy in treating advanced or metastatic bladder cancer.</p><p><strong>Trial registration: </strong>Funded by Pfizer Pharmaceuticals; AVETAX; https://classic.</p><p><strong>Clinicaltrials: </strong>gov/ct2/show/NCT03575013, NCT03575013.</p>\",\"PeriodicalId\":23408,\"journal\":{\"name\":\"Urologic Oncology-seminars and Original Investigations\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-05-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urologic Oncology-seminars and Original Investigations\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.urolonc.2025.04.005\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologic Oncology-seminars and Original Investigations","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.urolonc.2025.04.005","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Avelumab and taxol chemotherapy in platinum-refractory or ineligible metastatic urothelial carcinoma (AVETAX trial).
Background and objective: This study investigates the role of taxanes and immunotherapy for inoperable advanced or metastatic urothelial carcinoma in patients unable to tolerate or refractory to platinum-based regimens. We aimed to determine the safety and estimate the efficacy of a combination of avelumab and docetaxel in treating advanced or metastatic urothelial carcinoma.
Methods: This phase 1b, single-arm, open-label clinical trial involved adults with advanced or metastatic urothelial carcinoma, progressing during or after platinum-containing chemotherapy, within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy, or ineligible for platinum regimens. Primary objectives were determining the maximum tolerated dose (MTD) of docetaxel with avelumab and estimating efficacy via the objective response rate (ORR). In Phase I, docetaxel (45, 60, 75 mg/m²) was combined with 10 mg/kg avelumab every 3 weeks for 6 cycles, followed by avelumab biweekly as maintenance. The expansion cohort received treatment at the MTD of 75 mg/m² docetaxel with 10 mg/kg of avelumab.
Results: Twenty-one patients with advanced or metastatic urothelial carcinoma were studied: 8 cisplatin-refractory and 13 cisplatin-ineligible. The 75 mg/m² dose of docetaxel with 10 mg/kg avelumab was safe, with 1 dose-limiting toxicity (neutropenic fever). The ORR was 52.4% (95% CI: 29.8%-74.3%). Median progression-free survival and overall survival were 14.6 months (95% CI: 2.8-15.8) and 16.6 months (95% CI: 13.2-not reached), respectively.
Conclusion: The combination of avelumab and docetaxel shows favorable safety and efficacy in treating advanced or metastatic bladder cancer.
Trial registration: Funded by Pfizer Pharmaceuticals; AVETAX; https://classic.
期刊介绍：
Urologic Oncology: Seminars and Original Investigations is the official journal of the Society of Urologic Oncology. The journal publishes practical, timely, and relevant clinical and basic science research articles which address any aspect of urologic oncology. Each issue comprises original research, news and topics, survey articles providing short commentaries on other important articles in the urologic oncology literature, and reviews including an in-depth Seminar examining a specific clinical dilemma. The journal periodically publishes supplement issues devoted to areas of current interest to the urologic oncology community. Articles published are of interest to researchers and the clinicians involved in the practice of urologic oncology including urologists, oncologists, and radiologists.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
